Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch ECG: a new frontier in heart attack detection?

NCT ID NCT07780942

Diagnosis Sponsor: Hospital General Universitario Santa Lucia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 27, 2026 · Updated 3 times

Summary

This study tests whether a smartwatch can record a 9-lead ECG that is as accurate as the standard 12-lead ECG for diagnosing ST-elevation myocardial infarction (STEMI), a severe type of heart attack. Researchers will compare the diagnostic agreement between expert cardiologists reading both types of recordings from patients with chest pain. The goal is to see if smartwatch ECGs are a reliable and feasible tool for rapid cardiac triage in an emergency setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ECG smartwatch recording (9-lead electrocardiogram)
What this could lead to
If proven accurate, smartwatch ECGs could enable faster, more accessible detection of heart attacks, potentially reducing treatment delays.
What could go wrong
This is an observational study with a relatively small number of participants. The smartwatch may not be as reliable as standard ECG, and technical issues could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of unselected patients presenting to the Emergency Department at Hospital Universitario Santa Lucía (Cartagena) who are evaluated by the on-call cardiologist for ischemic-profile chest pain. This represents a real-world clinical cohort in an acute setting. Patients with extreme hemodynamic instability (where an additional recording would delay critical emergency treatment) and those with baseline electrocardiogram alterations (such as prior left bundle branch block or pacemaker-mediated pacing) that preclude proper ST-segment interpretation are excluded from this population.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients evaluated by the on-call cardiologist for chest pain with an ischemic profile. Exclusion Criteria: * Patients with extreme hemodynamic instability where the additional recording would cause an ethically unacceptable delay in their treatment. * Patients with a prior diagnosis of left bundle branch block or pacemaker-mediated pacing. * Patients who decline participation in the registry.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chest pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chest Pain ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chest pain Stemi - ST-segment elevation myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital General Universitario Santa Lucia

    RECRUITING

    Cartagena, Murcia, 30202, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.